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Editor’s key points
† Fibrinogen concentrate is
increasingly used to
decrease bleeding after
cardiac surgery.
† However, it has the
potential to increase
thrombotic events and
safety data are lacking.
† This retrospective analysis
examined the effect of
fibrinogen administration
to a target of 2 g litre21 in
cardiac surgical patients.
† There was no increase in
mortality or adverse
outcomes, but more data
are required.
Background. Although infusion of fibrinogen concentrate is increasingly used in bleeding
patients after cardiac surgery, safety data are scarce. We aimed to evaluate the effect of
perioperative administration of fibrinogen concentrate on postoperative morbidity and
mortality in patients undergoing cardiac surgery.
Methods. During a 2 yr study period, 991 patients underwent cardiac surgery at a single
university centre and were eligible for propensity score (PS) matching. We matched 190
patients with perioperative infusion of fibrinogen concentrate (median dose 2 g) with 190
controls without fibrinogen administration. After PS matching, crude outcome was analysed.
Further, a multivariate logistic regression including additional risk factors for adverse outcome
was performed. The primary endpoint was a composite of mortality and the occurrence of
major cardiac and thromboembolic events within 1 yr. Secondary outcomes included
mortalityafter30daysand1yrandthecompositeofmortalityandadverseeventsafter30days.
Results. Theadministrationof fibrinogenconcentratewasnotassociatedwithan increased risk
formortalityandthromboembolicorcardiaceventswithin1yraftercardiac surgery [unadjusted
hazard ratio (HR) 0.91; 95% confidence interval (CI) 0.55–1.49; P¼0.697]. When using
multivariate logistic regression model, the HR for adverse outcome in patients with
administration of fibrinogen concentrate was 0.57 (95% CI 0.25–1.17; P¼0.101). Similarly,
the administration of fibrinogen concentrate did not adversely affect the secondary outcomes
when applying unadjusted andmultivariate regression analyses.
Conclusions.Our studystronglysuggests that theadministrationoffibrinogenconcentratesat
low dose is not associated with thromboembolic complications or adverse outcomes after
cardiac surgery.
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Fibrinogen plays a critical role in the coagulation process, and it
is increasingly recognized as one of the primary haemostatic
targets in perioperative bleeding after cardiac surgery.1–4
Accordingly, several studies have found that higher pre- and
postoperative fibrinogen concentrations were associated with
lower bleeding volumes.2 5–8 Therefore, perioperative preserva-
tion of fibrinogen and the infusion of fibrinogen concentrate in
the case of bleedingandhaemodilutionassociatedwith hypofi-
brinogenaemiamight be a key step in perioperative haemosta-
sis. Preliminary data suggest that the infusion of fibrinogen
concentrate reduced postoperative bleeding volumes and
transfusionrequirements.9–13 Incontrast,a recentstudyinclud-
ing 84 patients undergoing cardiac surgery questioned the
benefit in haemostasis resulting from the administration of
fibrinogen concentrate or cryoprecipitate.7
In addition to the limited evidence regarding the appropriate
indication, dosing, and efficacy of fibrinogen concentrate in the
perioperative treatment of the bleeding patient undergoing
cardiac surgery,14–16 fibrinogen is a procoagulatory drug,
which could potentially cause thromboembolic complications
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and impair patient outcome. High fibrinogen levels are recog-
nized as a risk factor for increased mortality in non-surgical
patients.17 18 In surgical patients, a high preoperative fibrinogen
levelhasbeen identifiedasrisk factor for thedevelopmentofvein
graft stenosis after peripheral vascular surgery19 and has been
associated with increasedmortality after coronary surgery.20
Atour institution,fibrinogenconcentrate is regularlyadminis-
tered to bleeding patients after cardiac surgery. In this retro-
spective analysis of prospectively collected data, we aimed
to evaluate the association between perioperative administra-
tion of fibrinogen concentrate to bleeding patients undergoing
cardiac surgery and postoperative thromboembolic events and
mortalityafter30daysand1yr.Wehypothesizedthatfibrinogen
administration would increase neither postoperative thrombo-
embolic and cardiac events nor short- and long-termmortality.
Methods
Study design
With the approval of the local ethics committee (amendment
to EKBB 06/07, Ethikkommission beider Basel, Switzerland)
andwritten informed consent from all patients, we performed
a secondary retrospective analysis of prospectively collected
data at the University Hospital Basel. The original study has
recentlybeenpublished.21We includedall patientsundergoing
cardiac surgery between January 2008 and December 2009
with the exception of patients undergoing surgery of the
ascending aorta (with or without hypothermic circulatory
arrest) or pericardiectomy. All patients fulfilling inclusion
and exclusion criteria were eligible for propensity score (PS)
matching (Fig. 1).
Perioperative management
Patientswere orally premedicatedwithmidazolam (7.5mg) or
bromazepam (1.5–3 mg). Anaesthesia was induced by thio-
pental (3–4mgkg21) oretomidate (0.2–0.3mgkg21) and fen-
tanyl (2–6mgkg21).Anaesthesiawasmaintainedby isoflurane
andmidazolam/fentanyl infusion or by isoflurane andpropofol
infusion.Neuromuscular blockwas inducedandmaintainedby
atracurium. For procedures requiring cardiopulmonary bypass
(CPB), systemic full-dose heparin (350 units kg21) was admi-
nistered as a bolus before cannulation with additional doses
to maintain an activated clotting time (ACT) .480 s (ACT
plusw System, Metronic, Mu¨nchenbuchsee, Switzerland). Tran-
examic acid (30 mg kg21) was given immediately after the
initial dose of heparin. CPB priming volume amounted to
2000 ml. Myocardial protection was achieved by intermittent
anterograde blood or crystalloid cardioplegia. For coronary
artery bypass grafting without CPB, heparin was initially admi-
nistered at a dose of 300 units kg21 with additional doses to
maintain ACT .350 s. No tranexamic acid was given during
off-pump procedures. Body temperature was maintained at
.328C during CPB and at .368C during off-pump surgery.
CPBweaningwasmanagedwith catecholamines at thediscre-
tion of the attending anaesthesiologist. Heparin reversal was
achieved by protamine aiming for ACT values within+10% of
the value before surgery.
The following triggers for infusion of fibrinogen concentrate
and transfusion of allogeneic blood products were used during
the perioperative period: fibrinogen concentrate was adminis-
tered to bleeding patients according to our ROTEMw algorithm
(FIBTEMw maximal clot firmness ,8 mm),22 or fibrinogen
plasma concentration,2 g litre21.23 Aminimumhaemoglobin
concentration of .65 g litre21 was required during CPB. After
CPB and in the intensive care unit (ICU), patientswith a haemo-
globin concentration of ,70 g litre21 were given red blood cell
(RBC) transfusion; patients with a haemoglobin concentration
of 70–100 g litre21 were treated according to the discretion of
the physician in charge when the following transfusion triggers
occurred: persistent bleeding, haemodynamic instability, and
signs of myocardial ischaemia. Patients with a haemoglobin
concentration of.100g litre21were not given RBC transfusion.
Fresh-frozen plasma (FFP) and platelets were given to clinically
bleeding patients according to our ROTEMw algorithm,22 in the
case of low platelet count (,50 000×109 litre21) or prolonged
prothrombin time. However, in a small minority of patients
with clinically massive bleeding or preoperative use of platelet
aggregation inhibitors, procoagulatory products were trans-
fused based on the judgement of the attending physician only.
Data collection and endpoint ascertainment
Trained research personnel prospectively collected detailed
data on patient characteristic, surgical techniques, blood trans-
fusion,pre-andpostoperative laboratorytesting,administration
of coagulation factor concentrates, and in-hospital course and
clinically important adverse events. Data on adverse events
Patients undergoing
cardiac surgery
2008–2009
n=1113
EXCLUDE
Surgery involving proximal
aorta (n=120) or
pericardiectomy only (n=2)
INCLUDE
Patients included in study
and eligible for PS matching
n=991
WHOLE COHORT
Patients without fibrinogen
administration
n=781
WHOLE COHORT
Patients with fibrinogen
administration
n=210
PS MATCHING
Patients without fibrinogen
administration
n=190 
PS MATCHING
Patients with fibrinogen
administration
n=190 
Fig 1 Flow chart of inclusion and exclusion. PS, propensity score.
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during hospitalization defined as thoracic re-exploration, acute
(new-onset) renal impairment, severe brain injury, stroke, pul-
monary, mesenteric or peripheral thromboembolism, myocar-
dial infarction, and coronary re-intervention were collected
during hospitalization and follow-up.
The primary endpoint was defined as the composite of all-
cause mortality, the occurrence of non-fatal major adverse
cardiac events defined as myocardial infarction, need for sub-
sequent surgical or percutaneous coronary intervention, con-
gestive heart failure requiring hospitalization within 1 yr after
surgery, and any thromboembolic event including stroke,mes-
enteric ischaemia, peripheral arterial thromboembolism, pul-
monary embolism, and deep vein thrombosis within 1 yr.
Secondary endpoints were the composite of death and non-
fatal major adverse cardiac or thromboembolic event within
30 days, and all-cause mortality within 30 days and 1 yr.
Data on events were prospectively collected from clinical
charts during hospitalization. Follow-up occurred by a mailed
questionnaire 1 yr after surgery. Patients or next of kin were
asked to complete a simple questionnaire on the occurrence
and date of any hospitalization within 1 yr after surgery, the
patient’s vital status, or both, respectively. If the question-
naire was not returned, we contacted the patient by tele-
phone for a semi-structured interview. The interviews were
conducted by a trained study nurse, blinded to all patient
data. If the questionnaire or the interview indicated that the
patient was hospitalized for any reason, we contacted the
hospital or the patient’s general practitioner to obtain the dis-
charge letters. If direct contact with a patient could not be
established, we asked the patient’s general practitioner to
provide the required health status information. Based on
this information, the occurrence of the endpoints during hos-
pitalization and follow-up was determined by two independ-
ent assessors blinded to all patient data according to the
pre-specified definitions. In the case of disagreement, con-
sensus was reached by discussion.
Statistics analysis
Patients with and without administration of fibrinogen concen-
tratewere comparedwith regard to continuous and categorical
baseline variables in the whole cohort and in PS-matched
cohort. The PS was calculated as the probability of administra-
tion of fibrinogen concentrate for each patient in the whole
cohort. Thebinaryendpoint ‘fibrinogenadministration’waspre-
dicted usinga logistic regressionmodel (propensitymodel). The
following 20 variables were included: age, gender, preoperative
fibrinogen concentration, haemoglobin, platelet count, inter-
national normalized ratio, C-reactive protein, preoperative left
ventricular ejection fraction, preoperative therapy with aspirin
or clopidogrel, preoperative treatment with vitamin K antago-
nists, history of arterial hypertension, diabetes, hypercholester-
olaemia, cerebral insult, peripheral artery occlusive disease,
atrial fibrillation, numeric EuroSCORE I,24 surgical procedure,
and CPB time. Twenty (10%) and 76 patients (10%) with and
without fibrinogen concentrate, respectively, were excluded
from PS matching because of incomplete data in any of the
matching variables. The 190 cases with administration of
fibrinogen concentrate were matched by PS with 190 controls
without administration of fibrinogen concentrate, yielding a
matched data set including 380 patients. The procedure
included nearest neighbour matching on the linear PS using a
maximum calliper width of 0.2 SD of the linear PS.25 The actual
calliper was 0.21, resulting in a good overlap of PS between
cases and the matched controls.
After PS matching, crude outcome was analysed in the
PS-matched cohort. In addition, univariate andmultivariate lo-
gistic regression models in the PS-matched cohort and in the
whole cohort were performed including different variables
with potential influence on outcome. In the multivariate
models, the following five independent variables were included
as theywere associatedwith adverse outcome in the univariate
analysis: administration of fibrinogen concentrate (binary),
major bleeding (binary), peak postoperative troponin level (per
0.1 ng ml21 increase),21 26 number of administered allogeneic
blood products (continuous), and number of postoperative
complications unrelated to bleeding (‘other complications’)
(continuous). Major bleeding was defined as postoperative
bleeding volumes.1000mlduring 24hor theneed for surgical
re-explorationbecauseofbleeding.22Allogeneic bloodproducts
included RBC concentrates, platelet concentrates, and FFP.
Other postoperative complications included the need for
renal replacement therapy, mechanical circulatory support,
re-intubation, and sepsis.
Continuous data were presented as mean (SD) or as median
[inter-quartile range (IQR)] where appropriate. Categorical
data were presented as numbers and percentages. Cases and
controls were compared by Student’s t-test, Mann–Whitney
U-test, or x2 test where appropriate. Events were compared by
the Kaplan–Meier curves and the Cox proportional-hazards sur-
vivalmodel. Perioperative fibrinogen concentrations were com-
pared by a general linear model followed by Bonferroni’s post
hoc test.
Assuming an incidence rate of 14%,26 resulting in 50
events in the PS-matched population, our sample size would
allow a robust logistic regression model including up to five
variables.27 A P-value of ,0.05 was considered significant.
Statistical analyses were performed using IBM SPSS Statistics
21 (IBM Corp., Armonk, NY, USA).
Results
Patients’ characteristics and details on cardiac surgery of the
whole cohort (n¼991) and the matched cohort (n¼380) are
provided in Tables 1 and 2, respectively. Thirty day and 1 yr
follow-up were complete in 99.5% and 99.2% in the whole
cohort, respectively, and in 100% in the matched cohort.
Table 3 compares postoperative bleeding volumes, use of allo-
geneicbloodproducts, and importantparametersaftercardiac
surgery in the PS-matched cohort.
Perioperative administration of fibrinogen
concentrates
In the fibrinogen group, the median (range) amount of fibrino-
gen administrationwas 0 (0–4) and 2 (0–21) g in the operation
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theatre and in the ICU, respectively. The median (range) total
amount of administeredfibrinogen concentratewas2 (1–25)g.
Perioperative fibrinogen concentrations in cases with
administration of fibrinogen concentrates and matched con-
trols are shown in Figure 2. The course of perioperative fibrino-
gen concentrations were similar in both groups (P¼0.815). All
postoperative fibrinogen concentrations were significantly
different from baseline values (all P,0.001). The correspond-
ing fibrinogen plasma concentrations in the whole cohort
were comparable (data not shown).
Mortality and combined endpoint incidences
In the PS-matched cohort, all-cause mortality within 30 days
and 1 yr was 7.1% and 8.4%, respectively (Fig. 3A). The com-
bined endpoint of mortality and adverse cardiac or thrombo-
embolic events after 30 days and 1 yr was reached in 7.4%
and 16.3%, respectively (Fig. 3B). Unadjusted hazard ratios
(HR) for the primary and secondary adverse outcomes in
patients with fibrinogen administration were between 0.79
[95% confidence interval (CI) 0.39–1.58] and 1.46 (95% CI
0.55–3.82) (P-values between 0.678 and 0.446) compared
with matched controls (Fig. 3A and B).
In the whole cohort, all-causemortality within 30 days and
1 yr was 5.1% and 7.1%, respectively. The combined endpoint
of adverse cardiac or thromboembolic events after 30 days
and 1 yr was reached in 7.0% and 14.3%, respectively. In the
whole cohort, unadjusted HRs for the primary and secondary
adverse outcomes in patients with fibrinogen administration
were between 1.19 (95% CI 0.81–1.75) and 1.56 (95% CI
0.80–3.04) (P-values between 0.495 and 0.194) compared
with matched controls.
Univariate andmultivariate logistic regressionmodels
In the univariate regression model, major bleeding, the peak
troponin levels, transfusion of blood products, and the occur-
rence of postoperative complications unrelated to bleeding
were associated with the primary endpoint, whereas the ad-
ministration of fibrinogen concentrate was not (Table 4). Uni-
variate HRs in the whole cohort were comparable (data not
shown). After multivariate adjustment, the administration of
Table 1 Patient characteristics and details on cardiac surgery in the whole cohort. Data are mean (SD), median (IQR), or number of patients
(proportion). P-values were calculated by Student’s t-test, x2 test or Mann–Whitney U-test, where appropriate. CABG, coronary artery bypass
grafting; CRP, C-reactive protein; CPB, cardiopulmonary bypass; INR, international normalized ratio; LV-EF, left ventricular ejection fraction
All patients (n5991) Fibrinogen administration (n5210) No fibrinogen (n5781) P-value
Age (yr) 68 (61–76) 68 (60–76) 68 (61–75) 0.684
Male gender 727 (73) 166 (79) 561 (72) 0.038
Weight (kg) 80 (16) 78 (17) 80 (15) 0.209
Height (cm) 171 (9) 171 (9) 170 (9) 0.265
Haemoglobin (g litre21) 134 (16) 136 (17) 134 (16) 0.125
Haematocrit (litre litre21) 39 (5) 39 (5) 38 (4) 0.126
Platelet count (×109 litre21) 270 (88) 247 (71) 276 (91) ,0.001
INR 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 0.976
CRP (mg litre21) 2.5 (1.0–6.4) 1.6 (0.6–4.0) 2.7 (1.2–6.8) 0.007
Fibrinogen (g litre21) 3.4 (0.8) 3.1 (0.7) 3.5 (0.8) ,0.001
Aspirin therapy 740 (75) 168 (80) 572 (73) 0.347
Clopidogrel therapy 205 (21) 63 (30) 142 (18) 0.001
Oral anticoagulants 131 (13) 32 (15) 99 (13) 0.319
Arterial hypertension 722 (73) 136 (65) 586 (75) 0.002
Diabetes, treated 242 (25) 43 (21) 199 (26) 0.129
History of stroke 81 (8) 20 (10) 61 (8) 0.413
Atherosclerosis 121 (12) 23 (11) 98 (13) 0.523
Atrial fibrillation 125 (13) 29 (14) 96 (12) 0.561
LV-EF (%) 56 (13) 54 (13) 56 (13) 0.051
EuroSCORE I24 5 (2–7) 5 (3–7) 5 (2–7) 0.971
Cardiac surgery 0.006
Single CABG 535 (54) 100 (48) 435 (56)
Off-pump 26 (3) 4 (2) 22 (3)
Single non-CABG 224 (23) 44 (21) 180 (23)
Two procedures 215 (22) 60 (29) 155 (20)
Three procedures 16 (1) 6 (3) 10 (1)
Emergent surgery 30 (3) 12 (5) 18 (2) 0.007
CPB time (min) 98 (77–126) 110 (86–143) 94 (76–123) ,0.001
Cross-clamp time (min) 62 (47–84) 71 (51–92) 60 (46–80) ,0.001
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fibrinogen was not associated with mortality or the combined
endpoint of mortality and adverse cardiac or thromboembolic
events after 30 days and 1 yr (Table 5). HRs for adverse events
in patients with administration of fibrinogen concentratewere
between0.48 (95%CI 0.37–1.13) and0.75 (95%CI 0.25–2.37)
(P-values between 0.651 and 0.090) for the various primary
Table 2 Patient characteristics and details on cardiac surgery in the cases and controls after PS matching. Data are mean (SD), median (IQR), or
numberof patients (proportion). P-valueswere calculatedbyStudent’s t-test,x2 test, orMann–WhitneyU-test,whereappropriate. CABG, coronary
artery bypass grafting; CRP, C-reactive protein; CPB, cardiopulmonary bypass; INR, international normalized ratio; LV-EF, left ventricular ejection
fraction
Fibrinogen (n5190) No fibrinogen (n5190) P-value
Age (yr) 68 (60–76) 68 (61–76) 0.712
Male gender 150 (79) 154 (81) 0.701
Haemoglobin (g litre21) 135 (17) 136 (16) 0.485
Platelet count (×109 litre21) 248 (72) 252 (79) 0.575
INR 1.1 (0.3) 1.1 (0.3) 0.624
Fibrinogen 3.1 (0.7) 3.1 (0.6) 0.610
CRP (mg litre21) 1.6 (0.7–3.8) 1.7 (0.8–4.4) 0.761
Aspirin therapy 147 (77) 147 (77) 1.000
Clopidogrel therapy 52 (27) 49 (26) 0.816
Oral anticoagulants 28 (14) 30 (16) 0.887
Arterial hypertension 123 (65) 125 (66) 0.914
Hypercholesterolaemia 104 (55) 104 (55) 1.000
Diabetes, treated 40 (21) 47 (25) 0.464
Peripheral atherosclerosis 21 (11) 27 (14) 0.440
History of stroke 17 (9) 19 (10) 0.861
Atrial fibrillation 26 (14) 26 (14) 1.000
LV-EF (%) 55 (13) 54 (13) 0.722
EuroSCORE I24 5 (3–7) 5 (3–7) 0.457
Cardiac surgery 0.265
Single CABG 87 (45) 93 (49)
Off-pump 3 (2) 3 (2)
Single non-CABG 42 (22) 45 (24)
Two procedures 55 (29) 50 (26)
Three procedures 6 (3) 2 (1)
CPB time (min) 110 (86–144) 104 (86–144) 0.638
Table 3 Postoperative complications and transfusion of blood products. Data aremedian (IQR) or numbers of patients (proportion). P-valueswere
calculated by the Mann–Whitney U-test or x2 test, where appropriate. FFP, fresh-frozen plasma; PCC, prothrombin complex concentrate; RBC, red
blood cell
Fibrinogen (n5190) No fibrinogen (n5190) P-value
Highest creatinine level (mmol litre21) 101 (80–135) 96 (82–123) 0.525
Renal replacement therapy 8 (4) 7 (4) 1.000
Bleeding volume, postop (ml) 1100 (650–1750) 750 (500–1100) ,0.001
Surgical re-exploration because of bleeding 39 (21) 13 (7) ,0.001
Major bleeding 63 (30) 18 (10) ,0.001
Median fibrinogen dose 2 (2–4) 0 (0–0) ,0.001
Patients with PCC administration 39 (21) 3 (2) ,0.001
Median PCC dosage 0 (0–2400) 0 (0–2400) 0.591
RBC concentrate (units) 3 (1–5) 1 (0–2) ,0.001
Patients with RBC transfusion 163 (86) 111 (58) ,0.001
FFP concentrate (units) 0 (0–4) 0 (0–0) ,0.001
Patients with FFP transfusion 78 (40) 25 (13) ,0.001
Platelet concentrate (units) 0 (0–0) 0 (0–0) ,0.001
Patients with platelet transfusion 41 (22) 8 (4) ,0.001
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and secondary endpoints. Whereas postoperative complica-
tions were consistently associated with adverse outcomes
and mortality, the transfusion of allogeneic blood product
was not. Major bleeding was associated with adverse
outcome in the combined endpoints after 30 days and 1 yr.
Discussion
The results of the present study suggest that perioperative
administration of fibrinogen concentrate to bleeding patients
undergoing cardiac surgery is not associated with increased
incidence of major adverse cardiac and thromboembolic
events and mortality after 30 days and 1 yr. These findings
were consistently demonstrated both in a PS-matched case–
control analysis and inamultivariate logistic regressionmodel.
Fibrinogen concentrates are licensed for the treatment of
acquired hypofibrinogenaemia only in some European coun-
tries.3 However, its administration has been advocated by the
recent European guidelines on the management of severe
perioperative bleeding as a 1C recommendation.28 While the
evidence for this recommendation is still debated,14 29 data on
the risk of potential thrombotic events are limited. Based on6
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Table 4 Univariate model for the primary endpoint in the
PS-matched population. CI, confidence interval; HR, hazard ratio;
ICU, intensive care unit; PCC, prothrombin complex concentrate
Combined endpoint 1 yr HR 95% CI P-value
Fibrinogen administration, yes
vs no
0.906 0.553–1.486 0.697
Administration of PCC 1.367 0.675–2.769 0.385
Highest troponin concentration 10.958 4.816–27.933 ,0.001
Major bleeding, yes vs no 3.115 1.894–5.121 0.001
Postoperative sepsis, yes vs no 11.558 4.552–29.346 ,0.001
Renal replacement therapy, yes
vs no
5.991 2.946–12.182 ,0.001
Mechanical circulatory support,
yes vs no
5.897 3.136–11.087 ,0.001
Re-intubation on ICU, yes vs no 8.389 3.783–18.606 ,0.001
Number of allogeneic blood
products
1.041 1.021–1.061 ,0.001
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the post-market surveillance data, thromboembolic complica-
tions directly associated with the administration of fibrinogen
concentrate seem to be uncommon.30 However, the incidences
of thromboembolic complications based on the post-market
vigilance underestimate the actual event rates;23 and higher
incidences might occur in cardiac surgery where postoperative
cardiac and thromboembolic events are common.26 A recent
Cochrane review identified only three randomized controlled
trials including 124 patients—of them 61 patients with fibrino-
gen therapy—addressing the risk of thrombotic events after
the administration of fibrinogen concentrate.16 Our study add
further evidence suggesting that perioperative administration
of fibrinogen concentrate in patients undergoing cardiac
surgery might not increase the risk of postoperative adverse
outcomes including thrombotic events.
Fibrinogen is the coagulation factor present in the highest
concentration in blood and has a key role in haemostasis.3
However, several previous studies observed an association of
elevated fibrinogen concentrations and the increased risk for
both cardiovascular disease,31–33 venous thrombosis,34 and
vein graft stenosis.19 The potential causative association has
been questioned for several reasons.35–37 First, genetic poly-
morphisms seem to bemore important in the individual risk as-
sessment.35 Secondly, fibrinogen is up-regulatedwith the acute
phase reactionandappears tobean importantmarkerof severe
atherosclerosis and inflammatory state rather than a causative
factor.38 Thirdly, fibrin clot structuremight bemore relevant for
thromboembolic risk assessment than the fibrinogen concen-
tration itself,35 and increased fibre density and resistance to
fibrinolysis might essentially contribute to the increased risk
for cardiovascular diseases and thrombosis.39 40
Further, bleedingaftercardiac surgery leads to lossandcon-
sumption of all procoagulants. Whereas thrombin generation
seemstobe relativelywell preservedduringblood lossandcon-
secutivehaemodilution,1 41 42 fibrinogenhas been shown tobe
the first clotting factor to reach critically low concentrations.43
Accordingly, both preoperative and postoperative fibrinogen
concentrations have been shown to be predictive of post-
operative bleeding in patients undergoing coronary artery
bypassgraft (CABG) surgery.5–7 Two recentclinical studiessug-
gested that a postoperative fibrinogen concentration of ,2 g
litre21 was associated with increased postoperative bleeding
volumes.2 5 Fibrinogen substitution aiming for such levels
might, therefore, be a key step in managing postoperative
bleeding after cardiac surgery.11 Our data provide no evidence
that fibrinogen substitution in acquired hypofibrinogenaemia
aiming to achieve plasma concentrations in the lower normal
range (i.e. 2 g litre21) is associated with increased thrombo-
embolic events, mortality, or both.
The lack of an increased thromboembolic risk after fibrino-
gen administration in our study is in agreement with several
clinical and experimental studies.9 30 44 45 This might, at least
inpart, beexplainedbyseveral factors. First, the riskofoverdos-
ing fibrinogen may be counteracted both by increased
consumption of fibrinogen during haemorrhage and by hae-
modilution.42 Secondly, fibrin clot structure, an important
factor for thrombotic potential,35 is relevantly dependent on
thrombin generation.1 In haemodilution, clot structure is
presumed to be loose and having larger pores, which lead to
reduced clot firmness, and prone to fibrinolysis.41 Thirdly,
fibrin clot structure is affected by both aspirin and statins
which have been reported to reduce fibrin fibre density and in-
creasefibrinolysis rates.35Fourthly,besides its important role in
haemostasis and clot formation, fibrinogen exerts an anti-
coagulant function by binding thrombin with high affinity, by
modulating thrombin activity, and by inhibiting thrombin-
mediated factor V activation.1 46 Fibrinogen has, therefore,
been previously described as antithrombin I.47 Finally, fibrino-
gen concentrations showed rapid recovery after cardiac
surgery, which is well explained by high production rate in
Table 5 Multivariatemodels for primaryand secondary endpoints.
CI, confidence interval; HR, hazard ratio
HR 95% CI P-value
Combined endpoint 1 yr
Fibrinogen administration,
yes vs no
0.572 0.251–1.171 0.101
Major bleeding 3.292 1.717–6.314 ,0.001
Number of allogeneic blood
products
0.996 0.964–1.030 0.824
Number of other
postoperative complications
2.012 1.399–2.894 ,0.001
Highest troponin
concentration
5.998 1.794–20.057 0.004
Mortality 1 yr
Fibrinogen administration,
yes vs no
0.478 0.367–1.126 0.090
Major bleeding 1.793 0.678–4.737 0.239
Number of allogeneic blood
products
1.020 0.981–1.060 0.328
Number of other
postoperative complications
3.907 2.519–6.058 ,0.001
Highest troponin
concentration
1.143 0.198–6.590 0.881
Combined endpoint 30 days
Fibrinogen administration,
yes vs no
0.532 0.220–1.289 0.162
Major bleeding 3.955 1.581–9.895 0.003
Number of allogeneic blood
products
1.016 0.982–1.051 0.369
Number of other
postoperative complications
1.754 1.159–2.654 0.008
Highest troponin
concentration
6.783 2.149–21.406 0.001
Mortality 30 days
Fibrinogen administration,
yes vs no
0.753 0.243–2.339 0.624
Major bleeding 1.658 0.466–5.925 0.435
Number of allogeneic blood
products
1.029 0.989–1.071 0.155
Number of other
postoperative complications
2.612 1.512–4.512 0.001
Highest troponin
concentration
2.549 0.364–17.857 0.346
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the liver of2–5 gday21. In agreementwith a former study,48
this postoperative recovery of fibrinogen concentrations
was comparable in the groups with and without fibrinogen
substitution.
In contrast, other clinically used procoagulatory drugs [e.g.
prothrombin complex concentrates (PCC) or recombinant acti-
vated factor VII (rFVIIa)] that mainly increase thrombin gener-
ation are known to be associated with increased risk for
thromboembolism. The administration of rFVIIa on an off-label
basis, such as bleeding after cardiac surgery, has been reported
to be associated with the increased risk of arterial thrombo-
embolic events and tobeassociatedwith increasedmortality.49
Similarly, the administration of PCC, which is regularly used off-
label in the perioperative setting, might be potentially deleteri-
ous, especially when given in high dosages. Despite a low
event rate of only 1:31 000 reported in a pharmacovigilance
study,50 a recent meta-analysis found an overall incidence of
thromboembolic events of 1.4% (95% CI 0.8–2.1) in patients
receiving PCC for the reversal of vitamin K antagonists.51
The strengthsof our study includeahighnumberof patients
treated with fibrinogen concentrate, .99% completeness in
follow-up, the blind event adjudication by two independent
readers, and a close match between cases and controls.
Further, the event incidence in thematched cohort essentially
equalled that from the whole cohort, supporting its represen-
tativeness. Finally, the validity of our results is supported by a
dual statistical approach (case–control analysis andmultivari-
able logistic model) resulting in similar findings. Further, ana-
lysis in the PS-matched cohort and the whole cohort were
comparable. On the other hand, we are aware of the following
limitations of our study: first, the optimal design to assess a
medical intervention and drug efficacy is a randomized con-
trolled study. Our goal was not to assess the efficacy but the
safety of fibrinogen concentrate, and randomized studies are
rarely powered to address safety issues, given a low event
rate of adverse events. However, although the present data
do not suggest an increased risk of adverse events andmortal-
ity after fibrinogen administration at a median dose of 2 g, we
cannot exclude that higher dosages or more liberal fibrinogen
infusion triggers would have resulted in an increased risk of
major cardiac and thromboembolic events. Secondly, a small
minority of patients were not treated according to a strict
transfusion protocol and a strict definition of postoperative
massive bleeding. Fibrinogen and allogeneic blood transfusion
were transfused without previous testing because of unavail-
ability of ROTEMw and long turn-around times of conventional
coagulation testing because of severe bleeding. However, we
do not think that this limitation relevantly influenced our find-
ings because ROTEMw or conventional coagulation testing
were performed in 95% of the patients, and because all the
patients were treated similarly. Thirdly, bleeding volumes and
transfusion of allogeneic blood products were significantly
higher in the fibrinogen group. In agreement, the number of
postoperative complications including surgical re-exploration
or cardiac supportive therapy was significantly higher in the fi-
brinogen group. This might have resulted in the slightly higher
rate of adverse events and deaths in the unadjusted analysis,
whereas in the logistic regression model, the administration
tended to be favourable as evidenced by an HR of 0.5–0.75.
Finally, the number of included patients may not have been
sufficient to detect small differences between the two
groups, given the low incidence rate.We refrained from includ-
ing more than five variables into our multivariable analysis to
avoid overfitting.27
To conclude, fibrinogen supplementation inbleedingpatients
hasbeenrecommendedintherecentguidelinesbytheEuropean
SocietyofAnaesthesiologists,28despite limitedevidence regard-
ing efficacy and safety of such a policy.12 14 Our data suggest
that fibrinogen substitution (median dose of 2 g) aiming for
plasma fibrinogen levels of 2 g litre21 in bleeding patients
undergoing cardiac surgery is not associated with increased
mortality or thromboembolic and cardiac events after 1 yr. On
theotherhand, postoperative complicationsandmajorbleeding
were important predictors of postoperative mortality and mor-
bidity. Additional studies are required to further evaluate the
clinical efficacy and low thromboembolic risk of fibrinogen
concentrate.
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